As Southern California’s life-sciences ecosystem grows, Orange County has become a source of development — but is falling ...

Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

In a report released today, Matt Miksic from Barclays reiterated a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

First quarter earnings reports from Edwards Lifesciences Corp., Intuitive Surgical Inc. and Boston Scientific Corp. support trends seen earlier: Larger med-tech companies expect substantial tariff ...

Shares of Edwards Lifesciences Corp. EW rose 6.63% to $75.13 Thursday, on what proved to be an all-around great trading ...

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong ...

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Fintel reports that on April 24, 2025, Piper Sandler upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Neutral ...

Q1 2025 Management View CEO Bernard Zovighian outlined that total company sales grew 8% to $1.41 billion in Q1 2025, driven ...

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Analysts are estimating that Edwards Lifesciences will report an earnings per share (EPS) of $0.59. The announcement from ...